Related Experiment Video

Updated: Sep 21, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

615

Successful treatment of Kimura disease with benralizumab

Vivian G Szeto1, Benjamin Chin-Yee2, Mina Dehghani2

  • 1Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.

Annals of Hematology
|May 27, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Author Spotlight: Developing a Safer and More Efficient Treatment Protocol for Wasting Marmoset Syndrome (WMS)
03:07

Author Spotlight: Developing a Safer and More Efficient Treatment Protocol for Wasting Marmoset Syndrome (WMS)

Published on: July 12, 2024

1.2K
Rapid Depletion of Renal Macrophages using Human CD59/Intermedilysin Cell Ablation Tool
10:15

Rapid Depletion of Renal Macrophages using Human CD59/Intermedilysin Cell Ablation Tool

Published on: May 9, 2025

343

Related Experiment Videos

Last Updated: Sep 21, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

615
Author Spotlight: Developing a Safer and More Efficient Treatment Protocol for Wasting Marmoset Syndrome (WMS)
03:07

Author Spotlight: Developing a Safer and More Efficient Treatment Protocol for Wasting Marmoset Syndrome (WMS)

Published on: July 12, 2024

1.2K
Rapid Depletion of Renal Macrophages using Human CD59/Intermedilysin Cell Ablation Tool
10:15

Rapid Depletion of Renal Macrophages using Human CD59/Intermedilysin Cell Ablation Tool

Published on: May 9, 2025

343

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

243
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
243
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278

Articles linked to this work by shared authors, journal, and citation graph.

Over reliance on prior expectations in relapsing remitting multiple sclerosis.

iScience·2026

Perspectives of people affected by cancer toward generative AI in oncology: A scoping review of applications, evidence gaps, and future priorities.

European journal of cancer (Oxford, England : 1990)·2026

Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study.

The Lancet. Haematology·2026

Acquired Amegakaryocytic Thrombocytopenia With Evolution Toward Aplastic Anemia Treated With Thrombopoietin Receptor Agonists: A Case Report.

Case reports in medicine·2026

Generics in science communication: Misaligned interpretations across laypeople, scientists, and large language models.

Public understanding of science (Bristol, England)·2026

Transfusion-induced hemolysis in warm autoimmune hemolytic anemia with autoantibodies that have anti-e specificity: a case report and systematic review of the literature.

Therapeutic advances in hematology·2026

Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation.

Annals of hematology·2026

Optimizing venetoclax duration with hypomethylating agents for newly diagnosed acute myeloid leukemia: impact on response and survival.

Annals of hematology·2026

Defining and managing high-risk acute myeloid leukemia (AML) in 2026.

Annals of hematology·2026

Durable CNS remission with elranatamab and intrathecal therapy in relapsed/refractory multiple myeloma.

Annals of hematology·2026

Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia.

Annals of hematology·2026

Change in COVID-19 outcomes in lymphoma patients across pandemic waves: results of the COVID-19-lymphoma registry of the Bavarian Cancer Research Center (BZKF) 2020-2022.

Annals of hematology·2026

Immune context governs stage-specific responses to depleting anti-PD-1 antibody in type 1 diabetes.

Cell biomaterials·2026

Corrected Version: IL-12 p40 Monomer is Different from Other IL-12 Family Members to Selectively Inhibit IL-12Rβ1 Internalization and Suppress EAE.

Journal of clinical & experimental immunology·2026

Correction: Editorial: Immunological mechanisms, clinical presentations, and outcomes of neurological toxicities induced by immune checkpoint inhibitors.

Frontiers in immunology·2026

Clinical Outcomes of Transabdominal Preperitoneal and Totally Extraperitoneal Inguinal Hernia Repair.

JSLS : Journal of the Society of Laparoendoscopic Surgeons·2026

Immune Roles of Canonically Non-Immune Cells in Biomaterials Response.

Cell biomaterials·2026

Anti-CD38 monoclonal antibodies in multiple myeloma and beyond: immunotherapeutic mechanisms, evidence maturity, and clinical positioning.

Frontiers in immunology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us